
USD
+$0.00
(+0.00%
)At Close (As of Dec 12, 2025)
$3.51M
Market Cap
-
P/E Ratio
-19.5
EPS
$28.60
52 Week High
$1.52
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$8.4M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | - |
| Capital Expenditures | $0 |
| Change In Receivables | - |
| Change In Inventory | - |
| Profit Loss | - |
| Cashflow From Investment | $7.8M |
| Cashflow From Financing | $112K |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$9.8M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Artelo Biosciences Inc. (ARTL), headquartered in La Jolla, California, is a clinical-stage biopharmaceutical firm focused on developing innovative therapies that utilize the endocannabinoid system to tackle a range of medical challenges. The company aims to enhance cannabinoid efficacy through its diverse pipeline, which primarily targets oncology, pain management, and appetite stimulation. With a commitment to scientific rigor and compliance with regulatory standards, Artelo is poised to address significant unmet needs in the cannabinoid therapeutics sector, presenting a compelling opportunity for institutional investors seeking growth in the biopharmaceutical space.